Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News 2014

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million

December 18, 2014 – Completion of alternative public offering in which Pieris AG becomes a wholly-owned subsidiary of Pieris Pharmaceuticals, Inc. Freising, Germany – Pieris Pharmaceuticals, Inc. (OTC:PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a…

Related to: Pieris Pharmaceuticals Inc.

The 25th treatment center of Fysius Rugexperts is a fact!

December 18, 2014 – Press release only available in Dutch: Het 25e behandelcentrum van Fysius Rugexperts is een feit!

Related to: Fysius Back Clinics

Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia

December 2, 2014 – recAP shown to improve skeletal and dental mineralisation in potentially new indication with high unmet medical need. Bunnik, The Netherlands - AM?Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory…

Related to: AM-Pharma

Ascendis Pharma AS Completes $60 Million Oversubscribed Series D Financing

December 1, 2014 – Utrecht, The Netherlands and Copenhagen, Denmark - Ascendis Pharma A/S, a biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced the successful completion of a $60 million Series D financing.  New investors…

Related to: Acacia Pharma

Gilde Healthcare portfolio company Definiens acquired by MedImmune

November 4, 2014 – Trade sale marks success of portfolio company in Digital Health, an emerging theme in healthcare Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, today announced it has agreed to…

Related to: Definiens

Acacia Pharma Announces Positive Phase III Results in Post-Operative Nausea and Vomiting (PONV)

October 8, 2014 – Utrecht, the Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces that its portfolio company Acacia Pharma (Cambridge, UK) announces positive Phase 3 results with APD421 for the management…

Related to: Acacia Pharma

Levicept Ltd closes £10 million financing round

October 7, 2014 – Sandwich, UK – Levicept Ltd., a biopharmaceutical company focused on the development of LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc) for chronic pain indications, announces that it has closed a £10 million Series A financing with Advent Life Sciences, Gilde Healthcare…

Related to: Levicept

Gilde Healthcare Portfolio Company ProQR raises $97.5M in bumped up IPO

September 19, 2014 – Utrecht, the Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces that its portfolio company ProQR Therapeutics priced its initial public offering of 7,500,000 ordinary shares at an initial…

Related to: ProQR Therapeutics

AM-Pharma Closes €12.2 million Financing Round

September 11, 2014 – Bunnik, The Netherlands - AM?Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that it has closed a €12.2 million financing round led by Gilde Healthcare. Existing investors…

Related to: AM-Pharma

Prosonix’ Marketing Authorisation Application for PSX1001 Under Assessment in EU

September 2, 2014 – Triggers milestone payment from Mylan OXFORD, UK – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that its Marketing Authorisation Application (MAA) for PSX1001 has been validated and is being…

Related to: Prosonix

Gilde Healthcare realizes sixth exit in 12 months

August 26, 2014 – Sapiens acquired by Medtronic for $200 million in cash Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, today announces it has sold its stake in Sapiens Steering Brain Stimulation…

Related to: Sapiens

Sym004 Advances into Two New Clinical Trials and Receives Milestone Payments

August 7, 2014 – COPENHAGEN, Denmark 7 - Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that its collaborative partner, Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, Merck Serono has initiated two new clinical studies…

Related to: Symphogen

Successful Exit Gilde Healthcare Following Sale of Danish Biopharmaceutical Company Santaris

August 6, 2014 – Utrecht (the Netherlands) / Cambridge (USA) — Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces it has sold its minority stake in biopharmaceutical company Santaris Pharma A/S (Copenhagen, Denmark) to Roche (SIX: RO, ROG; OTCQX:…

Related to: Santaris Pharma

d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the

July 1, 2014 – Strategic alliance to provide services from virology assay development and testing to formulation of accelerated clinical development plans for drugs, biologicals, vaccines and diagnostics Parsippany, New Jersey, United States and Rotterdam, the Netherlands – d3 Medicine LLC, an…

Related to: Viroclinics Biosciences

Gilde Healthcare company Definiens closes €15M financing round to expand into digital tissue diagnos

June 23, 2014 – Definiens AG, a Munich, Germany-based provider of a tissue diagnostics platform aimed at helping physicians improve treatment announced that it has closed a round of financing for € 15 Million. The round was co-led by new investor Wellington Partners and existing investor Gilde Healthcare…

Related to: Definiens

Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer

May 19, 2014 – New Manufacturing Capabilities to Support early Development Mads Laustsen, formerly of CMC Biologics, Joins Symphogen 1 June 2014 COPENHAGEN, Denmark: Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announced…

Related to: Symphogen

Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients

May 12, 2014 – SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2b clinical trial of its lead drug candidate, emricasan,…

Related to: Conatus Pharmaceuticals

Agendia announces companion diagnostics agreement with Daiichi Sankyo

April 25, 2014 – IRVINE, CA and AMSTERDAM – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched…

Related to: Agendia

Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory

April 15, 2014 – OXFORD, UK, and PITTSBURGH – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world’s leading…

Related to: Prosonix

Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm

April 7, 2014 – EXETER, New Hampshire - Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3x5 Special Opportunity Fund, Integral Capital…

Related to: Vapotherm

Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial

March 3, 2014 – SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan,…

Related to: Conatus Pharmaceuticals

Symphogen Enters Clinical cGMP Manufacturing Agreement with Gallus

February 25, 2014 – Symphogen, A/S, a private biopharmaceutical company developing recombinant monoclonal antibody (mAb) mixtures for the treatment of cancer has signed a manufacturing agreement with Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization…

Related to: Symphogen

uniQure announces successful NASDAQ IPO

February 6, 2014 – Amsterdam, The Netherlands – uniQure, a Gilde Healthcare portfolio company, announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share raising $91.8 million and started trading under the symbol…

Related to: uniQure

Definiens Signs Agreement with Clarient to Offer Validated Solutions for Routine Clinical Pathology

February 3, 2014 – MUNICH - Definiens, the global leader in image analysis for digital pathology and diagnostics announced today the signing of an agreement with Clarient Diagnostic Services, Inc.- which extends the use of Definiens’ automated image analysis software and solutions in Clarient's validated…

Related to: Definiens

Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones

January 13, 2014 – Leveraging Orphan Drug Designation in Clinical Trial for Liver Transplant Recipients SAN FRANCISCO - (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease,…

Related to: Conatus Pharmaceuticals

Gilde Healthcare Services acquires majority share in Viroclinics Biosciences from Erasmus MC

January 7, 2014 – UTRECHT, THE NETHERLANDS – Gilde Healthcare Services has acquired a majority share in Viroclinics Biosciences (Viroclinics) a virology contract research organization, from Erasmus University Medical Center (Erasmus MC). The partnership between Viroclinics and Gilde Healthcare will…

Related to: Viroclinics Biosciences

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy
  • SFDR Disclosure